Rabitec

RSS

Rabies vaccine (live, oral) for foxes and raccoon dogs

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Rabitec. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Rabitec.

This EPAR was last updated on 07/01/2021

Authorisation details

Product details
Name
Rabitec
Agency product number
EMEA/V/C/004387
Active substance
attenuated live rabies vaccine virus, strain SPBN GASGAS
International non-proprietary name (INN) or common name
Rabies vaccine (live, oral) for foxes and raccoon dogs
Species
  • Red foxes (Vulpes vulpes)
  • Raccoon dogs (Nyctereutes procyonoides)
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI07BD
Publication details
Marketing-authorisation holder
CEVA Santé Animale
Revision
3
Date of issue of marketing authorisation valid throughout the European Union
01/12/2017
Contact address

10 avenue de La Ballastière
33500 Libourne
France

Product information

18/12/2020 Rabitec - EMEA/V/C/004387 - IAIN/0006/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Immunologicals for canidae

  • Live viral vaccines

Therapeutic indication

For the active immunisation of foxes and raccoon dogs against rabies to prevent infection and mortality.

Assessment history

Related content

How useful was this page?

Add your rating
Average
1 rating